Table 3.
Co-morbidities in hospitalized non-European patients (n = 389) with confirmed COVID-19 according to geographical area of origin
| Co-morbidity | Latin America,n (%) | Asia,n (%) | Africa,n (%) | Total, n (%) |
|---|---|---|---|---|
| Total | 354 (91) | 19 (4.9) | 16 (4.1) | |
| Diabetes mellitus | 44 (12.4) | 2 (10.5) | 6 (37.5) | 52 (13.4) |
| Hypertension | 81 (22.9) | 5 (26.3) | 7 (43.8) | 93 (23.9) |
| Chronic pulmonary disease | 41 (11.6) | 2 (10.5) | 3 (18.8) | 46 (11.8) |
| Chronic renal disease | 20 (5.6) | 2 (10.5) | 2 (12.5) | 24 (6.2) |
| Cardiovascular disease | 25 (7.1) | 1 (5.3) | 5 (26.3) | 31 (8) |
| Malignancy | 19 (5.4) | 1 (5.3) | 0 | 20 (5.1) |
| Immunosuppression | 30 (8.5) | 3 (15.8) | 3 (18.8) | 36 (9.2) |
| HIV-associated | 3 (0.8) | 1 (5.3) | 1 (6.3) | 5 (1.3) |
| Non-HIV-related | 27 (7.6) | 2 (10.5) | 2 (12.5) | 31 (7.9) |
Abbreviations: COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus.